Evidence map›Paper›PMID 38233724›Full record

SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Oral regimen for high dose methotrexate urine alkalinization: a systematic review and meta-analysis.

Romina Kaveh-Ahangaran, Mohammad Abdollahi, Mohammad Vaezi, Amir Kasaeian, Zhalleh Bahlouli, Ghasem Janbabaei, Amirmahdi Mojtahedzadeh, Mojtaba Mojtahedzadeh, Shirin Djalalinia, Bita Shahrami

Open access · greenAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Romina Kaveh-AhangaranHematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-8158-3708
Mohammad AbdollahiDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-0123-1209
Mohammad VaeziHematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-3186-5491
Amir KasaeianHematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-2018-9368
Zhalleh BahlouliDepartment of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ghasem JanbabaeiHematologic Malignancies Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-2651-6200
Amirmahdi MojtahedzadehFaculty of Medicine, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0003-0766-6748
Mojtaba MojtahedzadehDepartment of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-2160-9301
Shirin DjalaliniaDevelopment of Research and Technology Center, Deputy of Research and Technology, Ministry of Health and Medical Education, Tehran, Iran.ORCID http://orcid.org/0000-0002-9297-0834
Bita ShahramiHematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. bita.shahrami@gmail.com.ORCID http://orcid.org/0000-0002-5383-782X
Tehran University of Medical Sciences · IRMinistry of Health and Medical Education · IRSemmelweis University · HUShariati Hospital · IRStem Cell Technology Research Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUrine alkalinization prevents nephrotoxicity in patients receiving high-dose methotrexate (HDMTX). While the standard approach involves IV sodium bicarbonate, alternative oral bicarbonate regimens are crucial in drug shortages and outpatient settings. This study aims to review the efficacy and safety of such regimens.

methodsPubMed, WOS, and Scopus were systematically searched using the PRISMA protocol for relevant studies involving human subjects, including randomized clinical trials, retrospective, prospective, cohort, case reports, and case series studies. There were no restrictions on language, time, or age group. Qualified and eligible papers were used to extract data on efficacy and safety indicators, and the final relevant records were assessed for quality using the Risk of Bias in Non-Randomized Studies-of Interventions (ROBINS-I) assessment tool.

results12 studies with 1212 participants were included in the systematic review, with pooled data from 8 studies used for meta-analysis. No significant differences in mean differences (MDs) or odds ratio (OR) were found after the oral bicarbonate regimen, except for when urine pH fell to < 7 (MD: 0.91, 95% CI: 0.32, 1.5, P < 0.05) and the incidence of diarrhea (OR: 2.92, 95% CI: 1.69, 5.05, P < 0.05).

conclusionAn oral bicarbonate regimen is a safe and effective way to alkalize HDMTX urine, providing a viable and cost-effective alternative to IV protocols. Further prospective multicenter studies are necessary. Systematic review registration identifier: CRD42023379666.

Indexed as

MethotrexateAdministration, OralHumansHydrogen-Ion ConcentrationSodium BicarbonateUrineMethotrexateSodium BicarbonateChemotherapyDrug ShortageMethotrexate (MTX)Sodium BicarbonateUrine Alkalinization

Identifiers

PMID38233724
PMCPMC11087431
OpenAlexW4390935712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.